Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

StemBANCC at the start – funded with EUR 55.6 M

18.12.2012
StemBANCC will start yet this year – an international research project involving 25 academic partners and 11 partners from the pharmaceutical industry.
Funded with a total budget of EUR 55.6 M, StemBANCC intends to develop new therapies for Alzheimer’s, Parkinson’s, diabetes and other major diseases. The 5-year project relies on knowledge from stem cell research, for improved active ingredients, and it will build a platform with a total of 1500 pluripotent stem cell lines, also known as induced pluripotent stem cells or iPS. For this iPS technology, the Nobel Prize in Medicine was awarded this year. NMI’s contribution to StemBANCC is its expertise in the field of electro-physiology.

Headed by Prof. Dr. Elke Guenther, head of the cell biology division at the NMI, her team of researchers is responsible for characterising the functioning of the stem cells and their pharmacological validation.

Currently, many drugs fail rather late in the drug development process because the tests used in the earlier stages of drug development simply do not reflect what happens in real life when the drug is administered in patients. This is partly because these early tests rely heavily on animal cells, and when human cells are used, they have often been extensively modified to survive in culture and so no longer behave naturally. Those working in drug research and development therefore urgently need a good supply of cells that more accurately mimic what happens in the human body.

The power of pluripotency
Most adult cells can only divide to produce other cells of the same type – for example, skin cells can only make other skin cells, and blood cells can only make other blood cells. Only embryonic stem cells are ‘pluripotent’, i.e. able to give rise to all the different kinds of cell that make up the human body. However, in recent years researchers have developed a way of reprogramming ordinary adult cells to create so-called induced pluripotent stem (iPS) cells. Like embryonic stem cells, iPS cells are able to generate any kind of cell; as such, they offer researchers a good supply of different kinds of human cell that can be used in research and drug development. The research resulting in the creation of the first iPS cells was a major scientific breakthrough that won scientists John Gurdon and Shinya Yamanaka the 2012 Nobel Prize in Physiology or Medicine.

A unique resource

STEMBANCC’s goal is to generate 1 500 iPS cell lines from 500 people, characterise them in terms of their genetic, protein, and metabolic profiles, and make them available to researchers. All cell lines will also undergo a rigorous quality check.

The raw materials for the project will be largely skin and blood samples taken from patients with certain diseases, people who display adverse reactions to drugs, and healthy individuals. The collection of these samples will be carried out with the individuals’ informed consent and in line with strict ethical standards.

There will be a strong focus on peripheral nervous system disorders (especially pain); central nervous system disorders (e.g. dementias); neurodysfunctional diseases (e.g. migraine, autism, schizophrenia, and bipolar disorder); and diabetes. The project will also investigate the use of human iPS cells for toxicology testing; here the team will use the iPS cells to generate liver, heart, nerve and kidney cells.

Ultimately STEMBANCC will be a source of well-characterised, patient-derived iPS cells that will help researchers study diseases, develop new treatments, and test the efficacy and safety of new drugs.

The Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA. www.imi.europa.eu

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n°115439, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

Dr. Nadja Gugeler | idw
Further information:
http://www.nmi.de/
http://www.biochipnet.com/

More articles from Awards Funding:

nachricht The quest for the oldest ice on Earth
14.11.2016 | Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung

nachricht Empa Innovation Award for new flame retardant
09.11.2016 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Predicting unpredictability: Information theory offers new way to read ice cores

07.12.2016 | Earth Sciences

Sea ice hit record lows in November

07.12.2016 | Earth Sciences

New material could lead to erasable and rewriteable optical chips

07.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>